Investor Relations Corporate ProfileAssembly Bio aspires to deliver innovative small molecule antiviral therapeutics designed to change the path of serious viral and liver diseases and improve the lives of patients worldwide. Minimum 15 minutes delayed. Source: LSEG Press Releases See all news Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026 Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program Events & Presentations See all upcoming events Nov 5 - Nov 9, 2026 American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2026 Sep 16, 2026 at 8:30 AM EDT H.C. Wainwright 28th Annual Global Investment Conference – Fireside Chat Jun 8, 2026 at 8:40 AM EDT Goldman Sachs Global Conference Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
Investor Relations Corporate ProfileAssembly Bio aspires to deliver innovative small molecule antiviral therapeutics designed to change the path of serious viral and liver diseases and improve the lives of patients worldwide. Minimum 15 minutes delayed. Source: LSEG Press Releases See all news Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026 Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program Events & Presentations See all upcoming events Nov 5 - Nov 9, 2026 American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2026 Sep 16, 2026 at 8:30 AM EDT H.C. Wainwright 28th Annual Global Investment Conference – Fireside Chat Jun 8, 2026 at 8:40 AM EDT Goldman Sachs Global Conference
